Description

PANTODAC 40 MG (1X15)

Indications

PANTODAC 40 MG is primarily indicated for the treatment of various gastrointestinal disorders related to excessive stomach acid production. These include gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. By effectively reducing gastric acid secretion, PANTODAC helps alleviate symptoms such as heartburn, acid regurgitation, and discomfort associated with these conditions. It is also used in the prevention of gastric ulcers associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs).

Mechanism of Action

The active ingredient in PANTODAC is Pantoprazole, a proton pump inhibitor (PPI). Pantoprazole works by irreversibly inhibiting the H+/K+ ATPase enzyme system located in the gastric parietal cells. This enzyme is responsible for the final step in gastric acid production. By blocking this enzyme, Pantoprazole effectively reduces the secretion of gastric acid, leading to increased gastric pH and providing relief from acid-related disorders.

Pharmacological Properties

Pantoprazole is well-absorbed after oral administration, with peak plasma concentrations typically reached within 2 to 4 hours. It has a bioavailability of approximately 77% when taken orally. The drug is extensively metabolized in the liver and has a half-life of about 1 hour, although its effects on acid secretion can last up to 24 hours due to its irreversible action on the proton pump. Pantoprazole is primarily excreted through urine and feces, with around 80% of the drug eliminated as metabolites.

Contraindications

PANTODAC should not be used in patients who are hypersensitive to Pantoprazole or any of the excipients in the formulation. Additionally, it is contraindicated in individuals with a history of severe liver impairment, as the metabolism of the drug may be significantly affected. Caution is advised in patients with osteoporosis, as long-term use of PPIs has been associated with an increased risk of bone fractures.

Side Effects

Common side effects of PANTODAC include headache, diarrhea, nausea, vomiting, flatulence, and abdominal pain. These side effects are generally mild and transient. However, more serious adverse effects can occur, such as an increased risk of Clostridium difficile infection in the colon, kidney disease, and vitamin B12 deficiency with prolonged use. Patients should be monitored for any unusual symptoms or side effects while on this medication.

Dosage and Administration

The recommended dosage of PANTODAC for adults is typically 40 mg once daily, taken before a meal. For the treatment of GERD, the duration of therapy may range from 4 to 8 weeks, depending on the severity of the condition. In cases of Zollinger-Ellison syndrome, the dosage may be adjusted based on individual patient needs and response to treatment. It is important to follow the prescribing physician’s instructions regarding dosage and duration of therapy.

Interactions

PANTODAC may interact with certain medications, potentially altering their effectiveness or increasing the risk of side effects. Notable drug interactions include those with warfarin, methotrexate, and certain antiretroviral agents. Patients taking other medications should inform their healthcare provider to assess the risk of interactions. Additionally, the absorption of drugs that require an acidic environment for optimal absorption, such as ketoconazole and atazanavir, may be impaired when taken concurrently with PANTODAC.

Precautions

Prior to initiating treatment with PANTODAC, a thorough medical history should be obtained, particularly regarding any existing liver disease, osteoporosis, or previous gastrointestinal disorders. Long-term use of PPIs has been associated with potential risks, including gastric cancer. Therefore, regular follow-up and reassessment of the need for continued therapy are recommended. Patients should also be advised to report any new or worsening symptoms during treatment.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of Pantoprazole in the management of acid-related disorders. A randomized controlled trial published in the American Journal of Gastroenterology showed that Pantoprazole significantly reduced symptoms of GERD compared to placebo, with a favorable safety profile. Another study highlighted its effectiveness in healing peptic ulcers, showing a higher healing rate compared to other PPIs. These studies support the use of PANTODAC as a reliable option for patients suffering from excessive gastric acid secretion.

Conclusion

PANTODAC 40 MG is an effective proton pump inhibitor that provides relief from various acid-related gastrointestinal disorders. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable therapeutic option. However, it is essential for patients to use this medication responsibly, adhering to prescribed dosages and being aware of potential side effects and drug interactions. Regular monitoring and consultation with healthcare providers can help ensure optimal treatment outcomes.